JRS PHARMA Introduces "A Tasteful New Design In Solid Dosage Form "PROSOLV® ODT G2 (Orally Disintegrating Excipient Matrix)"
Patterson, NY – JRS PHARMA, producer of world-leading excipient products and patented technologies for the pharmaceutical and nutritional industries, adds a new product to its extensive portfolio of high-quality multifunctional excipients: PROSOLV® ODT G2, (Microcrystalline cellulose, Colloidal silicon dioxide, Mannitol, Fructose, Crospovidone), an orally disintegrating excipient matrix for solid dosage form development and manufacture.
PROSOLV® ODT G2 is the second generation of our high functionality excipient for orally disintegrating tablet formulations with a creamy, smooth, cool mouth feel. PROSOLV® ODT G2 provides a pleasing, convenient and discreet form of administration for active pharmaceutical and nutritional ingredients without the need for water.
PROSOLV® ODT G2 offers the functional performance needed for today’s orally disintegrating tablet formulation challenges and complies with globally accepted and monographed raw materials, such as Ph. Eur., USP/NF, and JP/JPE.
PROSOLV® ODT G2 provides simple formulation development, manufacturing ease, patient compliance and faster time to market.
About JRS PHARMA:
JRS PHARMA LP offers innovative excipient products, patented technologies and technical expertise to the global pharmaceutical, nutritional, over- the-counter and generic companies. The broad JRS product line includes binders, fillers, disintegrants, lubricants, coatings used for solid oral dosage form development and manufacture.
SOURCE: JRS PHARMA